Every year, the Medicine Maker, a global publication with a focus on the people that drive the development of small and large molecule drugs as well as advanced therapies, compiles a list of pioneers and influencers advancing the knowledge frontier, driving clinical application, and fostering industry growth. The annual Medicine Maker Power List is compiled
On Monday, March 18, the Standards Coordinating Body convened for a workshop on standards. The group discussed how standards are critical for the transfer of novel technologies from academia to clinical use. The FDA’s Judy Arcidiacono, one of the keynote speakers, discussed how standards are imperative to building the foundation of regenerative medicine innovation. The
The Akron team recently attended the 4th Innate Killer Summit, held in in San Diego, California. The conference provided an excellent opportunity to participate in presentations and workshops covering cutting-edge research, recent clinical data, and commercial developments in the growing NK cell therapy market. More than 250 attendees collaborated and shared knowledge on ways we
The preservation of biological samples is critical to the success of experimental studies and clinical treatments in the emergent field of immunotherapy. Cryopreservation – keeping cells at sub-zero temperatures – slows metabolic activity significantly, enabling storage and transportation, as well as a return to functionality upon thaw. Of course, it’s not as simple as placing
Cell and gene therapies have demonstrated excellent clinical results across a range of indications with chimeric antigen receptor (CAR)–T cell therapies among the first to reach market. Although these therapies are currently manufactured using patient-derived cells, therapies using healthy donor cells are in development, potentially offering avenues toward process improvement and patient access. An allogeneic
From January 22 – 25, Phacilitate Leaders World and the World Stem Cell Summit will be co-located in Miami, FL. This popular event will attract 2,000 attendees, 150 exhibitors and 300 speakers representing every major stakeholder group. On January 22 at 3:20 pm, Dr. Claudia Zylberberg, CEO will be participating in a panel titled “SCB: Developing a standards
The MIT Center for Biomedical Innovation (CBI) leads the Biomanufacturing (BioMAN) program, an initiative that joins leaders from industry, academia, and government to address collective challenges in biologics manufacturing by creating a pre-competitive environment in which stakeholders can share best practices and engage in collaborative work. Akron Biotech attended this year’s summit in Cambridge, MA
This blog post was originally shared at standardscoordinatingbody.org. Claudia Zylberberg, SCB Board Member, Akron Biotech December 17, 2018 I’m pleased to announce that one of the first standards advancement projects SCB was involved in, Ancillary Materials Used in Cellular Therapy Production, has culminated in the publication of a three-part documentary ISO standard (ISO/TS 20399): Part
This week, from Wednesday November 7 through Sunday November 11, Akron Biotech representatives will be attending the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting at the Walter E. Washington Convention Center in Washington, D.C. SITC 2018 is the leading destination for scientific exchange, education and networking in the cancer immunotherapy field. As an innovative
As a scorching summer draws to a close and conference season begins, Akron will be participating at many upcoming events to further advocate for the use of higher quality ancillary materials in regenerative medicine processes. Our focus of providing affordable cGMP reagents throughout the development stages for these unique therapeutics serves to better ensure reproducibility
